Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is highly promising but requires robust T-cell expansion and engraftment. A T-cell defect in chronic lymphocytic leukemia (CLL) due to disease and/or therapy impairs ex vivo expansion and response to CAR T cells. To evaluate the effect of ibru...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Principais autores: Fraietta, Joseph A., Beckwith, Kyle A., Patel, Prachi R., Ruella, Marco, Zheng, Zhaohui, Barrett, David M., Lacey, Simon F., Melenhorst, Jan Joseph, McGettigan, Shannon E., Cook, Danielle R., Zhang, Changfeng, Xu, Jun, Do, Priscilla, Hulitt, Jessica, Kudchodkar, Sagar B., Cogdill, Alexandria P., Gill, Saar, Porter, David L., Woyach, Jennifer A., Long, Meixiao, Johnson, Amy J., Maddocks, Kami, Muthusamy, Natarajan, Levine, Bruce L., June, Carl H., Byrd, John C., Maus, Marcela V.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2016
Assuntos:
Immunobiology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4778162/
https://ncbi.nlm.nih.gov/pubmed/26813675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-11-679134
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados